Baker Bros. Advisors
Baker Bros. Advisors reported 79 stocks worth $21B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are INCY (17.8%), ONC (15.4%) and RVMD (10.4%). Compared with Q2 2026, the fund opened new positions in TRAX, SCTX and FRNM, added to ONC, KOD and CLDX, trimmed RVMD, CELC and ROIV and sold out of ALMS, VRDN and SION.
Latest filing: what Baker Bros. Advisors did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() INCY Incyte Corp | $3.7B | 17.8% | 30.8M | No change | 8 of 8 | |
| 2 | ![]() ONC Beone Medicines Ltd | $3.2B | 15.4% | 8.8M | +31K (+0%) | 8 of 8 | |
| 3 | ![]() RVMD Revolution Medicines Inc | $2.2B | 10.4% | 10.6M | −806K (−7%) | 8 of 8 | |
| 4 | ![]() KOD Kodiak Sciences Inc | $2.1B | 9.9% | 21.9M | +1.9M (+10%) | 8 of 8 | |
| 5 | ![]() MDGL Madrigal Pharmaceuticals Inc | $1.1B | 5.2% | 2.1M | No change | 8 of 8 | |
| 6 | ![]() INSM Insmed Inc | $1B | 4.8% | 8.8M | No change | 8 of 8 | |
| 7 | ![]() KYMR Kymera Therapeutics Inc | $968M | 4.6% | 8.7M | No change | 8 of 8 | |
| 8 | ![]() ACAD Acadia Pharmaceuticals Inc | $865M | 4.1% | 42.9M | No change | 8 of 8 | |
| 9 | ![]() GRAL Grail Inc | $564M | 2.7% | 4M | No change | 8 of 8 | |
| 10 | ![]() SMMT Summit Therapeutics Inc | $554M | 2.6% | 32.8M | No change | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
CRINETICS PHARMACEUTICALS IN | $88M | 2.4M |
![]() ALMS Alumis Inc | $56.6M | 2M |
![]() VRDN Viridian Therapeutics Inc | $43.8M | 2.4M |
![]() SION Sionna Therapeutics Inc | $17.6M | 400K |
![]() VSTM Verastem Inc | $9.5M | 2.5M |
🔒 Free account: see all 9.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Baker Bros. Advisors 13F FAQ
What does Baker Bros. Advisors own?
Baker Bros. Advisors reported 79 stocks worth $21B in its 13F filing for Q3 2026, filed Nov 16, 2026. The table above lists every position in the filing (the top 10 without an account).
What did Baker Bros. Advisors buy and sell in Q3 2026?
Compared with Q2 2026: 5 new positions, 7 added to, 11 trimmed and 9 sold out. New positions include TRAX, SCTX and FRNM. It sold all of ALMS, VRDN and SION.
When will Baker Bros. Advisors file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Baker Bros. Advisors's portfolio worth?
The Q3 2026 filing reports $21B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

























